Average R&D cost to develop new biopharma compound 2013-2025 · Average cost to develop a compound for biopharma companies from 2013 to 2025 (in billion U.S. dollars) Average peak sales forecast per new biopharmaceutical asset 2013-2025

September 16, 2024 - Biopharmaceutical companies are investing in R&D on an immense, global scale. The study indicates that global biopharmaceutical R&D investment is significant, totaling $276 billion across 4,191 global companies in 2021.

Report Summary: Biopharmaceutical R&D remained resilient in 2025, with investment and dealmaking increasingly concentrated in high value science, emerging biopharma, and China linked activity.

R&D funding: In 2023, global funding of biopharmaceutical research and development increased to $72Bn, up from $61Bn in 2022. In the same period, M&A activity jumped to $140Bn from $78Bn in 2022, while the median deal value fell for the second ...

October 24, 2024 - A recent study, titled Comprehensive Measurement of Biopharmaceutical R&D Investment, published in Nature Reviews Drug Discovery, reveals that global pharmaceutical R&D expenditures are significantly higher than previously reported.

June 30, 2026 - By 2025, China accounted for about 30 percent of the global biopharma pipeline, up from 2 percent just ten years earlier, and about one-fifth of global licensing deals, according to McKinsey research.

February 9, 2023 - Cross-border data transfers are critical to the research, development, and delivery of new biopharmaceutical medicines to prevent and treat medical conditions and improve patients’ health. Cross-border Data Analytics and R&D Collaboration. Cross-border data analytics can help speed the early identification of potentially useful drug candidates, shortening discovery timelines from years to months.

September 9, 2025 - Today, the United States leads the world in biopharmaceutical industry research and development (R&D), supporting nearly five million jobs and generating more than $1.65 trillion in economic output.

October 30, 2024 - Published in August in Nature Reviews Drug Discovery, the study found that global biopharma R&D investment hit $276 billion in 2021 — more than double the commonly cited estimates.

A three-year average global R&D spending of at least $200 million per year. PhRMA member companies have invested over $1 trillion dollars in R&D since 2000, establishing the biopharmaceutical sector as the most R&D-intensive industry in the U.S.

6 hours ago - According to the Pharmaceutical Research and Manufacturers Association (PhRMA), biopharmaceutical firms in the U.S. spent about $96 billion on R&D in 2023. In 2023, total R&D by biopharmaceutical firms in the U.S. accounted for over 20 percent of total sales.

3 weeks ago - Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.

October 8, 2024 - Commentary: In a recent article published by Amitah Chandra et al., the first ever comprehensive analysis of research and development (R&D) expenditure by the biopharmaceutical industry is conducted, where the authors find that all previous measures of R&D expenditure in this industry have grossly underestimated total research expenditures.

In addition, some studies have used proprietary databases on R&D spending or conducted survey research to estimate private and public investment in biopharmaceutical R&D. For instance, a 2022 study leveraged data from EvaluatePharma, a private database that tracks R&D, to study global biopharmaceutical R&D spending by sector in 2020.15 The authors found that the private sector, including venture capital and biopharmaceutical firms, contributed 74% of spending and the public and nonprofit sectors the remaining 26%. A 2020 study by the UK Clinical Research Collaboration used surveys in combination with publicly available data to analyze the breakdown of health-related R&D spending in the United Kingdom, estimating that, in 2018, 50% of R&D spending was by businesses; 43% by the public sector, including universities; and 7% by the charity sector.16

August 6, 2024 - Conventional understanding of the magnitude, intensity and productivity of R&D investment in the biopharmaceutical ecosystem is predominantly based on survey data from large, publicly listed biopharmaceutical companies (see Related links).

We are a dedicated plant-based research and biopharmaceutical drug development company. Our goal is to create patented formulations of plant-inspired, minimum essential mixtures for use as prescription medications.

February 6, 2026 - Pharmaceutical R&D spending worldwide will exceed 300 billion U.S. dollars in the upcoming years. The U.S. is the global leader in life sciences research.

This growing demand has led market players to actively invest in scaling up their research and development activities to introduce novel products for various indications. Moreover, the increased number of regulatory approvals for new products and existing products for treating a range of diseases is contributing to the global biopharmaceuticals market's growth during the forecast period.

June 22, 2026 - The oncology segment is one of the most dynamic and rapidly growing areas of the biopharmaceutical industry, driven by the increasing prevalence of cancer worldwide and the continuous advancements in cancer treatment. For instance, as per a report by WHO in 2024, cancer is a leading cause of global mortality, responsible for approximately 1 in every 6 deaths and impacting nearly every household.

July 10, 2025 - Trend #1: Portfolio optimization: Research and development (R&D) costs are on the rise. Several of the fastest-growing therapy areas are becoming increasingly crowded, including oncology, cardiometabolic, and immunology (see Measuring the return from pharmaceutical innovation).